Frayed Deals, Fraught Partners: Product Tweaks Complicate Agreements
This article was originally published in The Pink Sheet Daily
Executive Summary
Sub-licenses with universities can make headaches, too, as contracts come “out of the drawer” for closer scrutiny in hard times, panelists agree at recent Napa conference.
You may also be interested in...
Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings
In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.